2023
Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis
Feher A, Miller E, Peters D, Mojibian H, Sinusas A, Hinchcliff M, Baldassarre L. Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis. Rheumatology International 2023, 43: 849-858. PMID: 36894756, DOI: 10.1007/s00296-023-05294-6.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementLV-GLSSystemic sclerosisWorse survivalClinical indicationsImpaired left ventricular global longitudinal strainLeft ventricular global longitudinal strainPresence of LGECMR strainLV cardiac indexWorse LV-GLSLV ejection fractionCox regression analysisGlobal longitudinal strainLV cardiac outputGlobal radialCardiac indexOverall survivalRetrospective cohortEjection fractionPrognostic valueAdverse outcomesCardiac outputGadolinium enhancementRV strain
2021
Adverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization database
2020
Opportunities for improved cardiovascular disease prevention in oncology patients.
Bravo-Jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, Baldassarre LA, Manisty C, Ghosh AK, Guha A, Lopez-Mattei JC. Opportunities for improved cardiovascular disease prevention in oncology patients. Current Opinion In Cardiology 2020, 35: 531-537. PMID: 32649353, DOI: 10.1097/hco.0000000000000767.Peer-Reviewed Original ResearchConceptsCardiovascular disease preventionCancer patientsDisease preventionCardiovascular disease prevention guidelinesCardiac risk factor modificationCancer treatmentCardiometabolic disease managementDisease prevention guidelinesCardiovascular risk factorsHigh cardiovascular riskRisk factor modificationAdverse cardiovascular outcomesRisk of cardiotoxicityOngoing clinical trialsNonpharmacologic therapiesCardiovascular eventsCardiovascular outcomesCardiovascular riskOncology patientsCancer survivorsPrevention guidelinesAdverse outcomesFactor modificationCardiorespiratory fitnessRisk factors